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Abstract
Background—Several cardiovascular risk factors have been associated with the risk of atrial
fibrillation (AF). Limited and inconsistent evidence exists on the association of blood lipid levels
and lipid lowering medication use with AF risk.
Methods and Results—We analyzed 13,969 participants (25% African-American, 45% men)
free of AF at baseline from the Atherosclerosis Risk in Communities (ARIC) study. Fasting HDL
cholesterol (HDLc), LDL cholesterol (LDLc), triglycerides, and total cholesterol were measured at
baseline (1987–89) and each of three follow-up visits. Incidence of AF was ascertained through
2007. The association of the use of statins and other lipid lowering medications with AF was
estimated in 13,044 ARIC participants attending visit 2 (1990–92), adjusting for covariates from
the previous visit. During a median follow-up of 18.7 years there were 1433 incident AF cases.
Multivariable hazard ratios (HR) and 95% confidence intervals (CI) of AF associated with a one
standard deviation increase in lipid levels were: HDLc: 0.97 (0.91–1.04); LDLc: 0.90 (0.85–0.96);
total cholesterol: 0.89 (0.84–0.95); and triglycerides: 1.00 (0.96–1.04). Participants taking lipid
lowering medications had an adjusted HR (95% CI) of AF of 0.96 (0.82–1.13) compared to those
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not on medications, while those taking statins had an adjusted HR of 0.91 (0.66–1.25) compared to
those taking other lipid lowering mediations.
Conclusions—Higher levels of LDLc and total cholesterol were associated with a lower
incidence of AF. HDLc and triglycerides, however, were not independently associated with AF
incidence. No association was found between the use of lipid lowering medications and incident
AF.
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Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, currently affecting
over 2.3 million US adults, and that number is expected to more than double in the next 5
decades as the population ages.1 AF is associated with increased risks of heart failure, stroke
and cardiovascular death.2 Major predictors for AF include age, white race / European
ancestry, obesity, left ventricular hypertrophy, and hypertension, along with certain lifestyle
factors.3–6 Many of these predictors are also risk factors for coronary heart disease (CHD) or
heart failure (HF), which often precedes the onset of AF.2 Blood lipid levels, which are
established risk factors for CHD, could also influence the risk of AF. In fact, low HDL
cholesterol (HDLc) levels have been associated with a 20–40% increased risk of AF, with
no association seen between triglyceride levels and the risk of AF. 7–9 However, limited and
inconsistent data exist on the association of triglycerides, total cholesterol and LDLc
cholesterol (LDLc) with incident AF, especially independently of other components of the
metabolic syndrome. 10–14
Numerous studies have provided evidence of the effectiveness of statins in the prevention
and treatment of cardiovascular diseases, potentially beyond their lipid-lowering effect.15
Accordingly, it has been suggested that statins might be effective in preventing AF. 16
Randomized controlled trials have found that use of statins was significantly associated with
a decreased risk of post-operative AF, and a decreased recurrence of AF.17, 18 Decreases in
mortality and cardiovascular events have been observed in patients receiving statins after AF
diagnosis.19 However, observational data and clinical trial evidence have produced mixed
results regarding the impact of statins on the incidence of AF in otherwise healthy
populations. An observational study reported statin use reduced the risk of developing AF
independently of the reduction in serum cholesterol levels. 20 However, a large randomized
clinical trial (ALLHAT) showed no relationship between randomly assigned pravastatin use
and a reduction in incident AF, after a follow-up time of six years.8 These data are
consistent with a meta-analysis in which the analysis of randomized controlled trials showed
no significant effect of statins on AF incidence, but indicated statins significantly reduced
the relative risk of AF in observational studies.21 To the best of our knowledge, no
information exists on the effect of other lipid lowering medications on the risk of AF.
The present study estimates the association of participants’ blood lipid profile over time with
the incidence of AF in the Atherosclerosis Risk in Communities (ARIC) cohort, a
community-based study of cardiovascular disease in the US. We also assess whether use of
statins or other cholesterol lowering medications affects the risk of AF, taking advantage of
the large number of incident AF cases and ample follow-up time in the ARIC cohort.
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The ARIC study is a prospective cohort study of cardiovascular disease and atherosclerosis
risk factors. Participants at baseline (1987–1989) included 15,792 men and women aged 45–
64, recruited from four communities in the US (Washington County, MD; suburbs of
Minneapolis, MN; Jackson, MS; Forsyth County, NC). Participants were mostly white in the
Washington County and Minneapolis centers, only African-American in the Jackson center,
and included both races in Forsyth County. After the initial assessment, study participants
were examined three additional times (1990–92, 1993–95, 1996–98). Response rates for
surviving participants at each exam were 93%, 86% and 80% respectively. Additionally,
ARIC participants have received annual follow-up calls since baseline, and survivors have a
response rate of ≥ 90%. The study was approved by institutional review boards at each
participating center and all study participants provided written informed consent.
Ascertainment of atrial fibrillation
AF diagnoses were ascertained by three different sources in the ARIC study:
electrocardiograms (ECG) performed at study visits, hospital discharge codes, and death
certificates.3 At each ARIC study visit, a 10-second 12-lead ECG was performed using a
MAC PC cardiograph (Marquette Electronics Inc, Milwaukee, WI) and transmitted to the
ARIC ECG Reading Center for coding, interpretation and storage. All ECGs automatically
coded as AF were visually checked by a trained cardiologist to confirm AF diagnosis.22
Annual follow-up calls and review of local hospital discharges identified hospitalizations in
ARIC participants through the end of 2007. ICD-9-CM codes of 427.31 or 427.32 listed as a
discharge diagnostic code identified AF cases. AF events associated with cardiac surgery
were excluded in this study. Validity was sufficient as approximately 90% of the cases were
confirmed in a physician review of discharge summaries from 125 possible AF cases.3 AF
cases were also identified if codes ICD-9 427.3 or ICD-10 I48 were listed as a cause of
death. Most incident AF cases (> 98%) in this analysis were identified from hospital
discharge codes. In this analysis, the incidence date of AF was defined as the date for the
first ECG showing AF, the first hospital discharge coded as AF or when AF was listed as a
cause of death, whichever occurred earlier.
Assessment of lipid levels
Blood samples were collected at each visit following a fast of at least eight hours and sent to
the ARIC Central Lipid Laboratory for processing. Detailed procedures are available
elsewhere.23, 24 Briefly, total plasma cholesterol and triglycerides were determined by
enzymatic methods, HDLc was measured after dextran-magnesium precipitation, and LDLc
was calculated by the Friedewald equation25 in those with triglyceride levels under 400 mg/
dL.
Assessment of lipid-lowering medication use
The use of lipid-lowering medications was self-reported and confirmed by checks on
medications brought to each visit by the patient. Lipid medications were divided into two
categories: statins and other lipid medications. Included in the “other” category were niacin
(vitamin B3), bile sequestrants, fibrates, and other antihyperlipidemics. Participants taking
both statins and another type of lipid lowering medication were considered to be in the statin
category.
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Measurement of other covariates
At each study visit, participants underwent a physical exam and provided self-reported
information. Detailed procedures on covariate measurements are available elsewhere.23 At
each visit, prevalent HF was defined as the reported use of HF medication in the previous
two weeks, presence of HF according the Gothenburg criteria (only at the baseline visit), or
having developed incident HF from the previous visit. 26 Incident HF was defined as the
presence of ICD-9-CM code 428 in any hospitalization during follow-up.27 Prevalent CHD
was defined as prior cardiovascular revascularization, physician-diagnosed myocardial
infarction, or presence of a previous myocardial infarction by ECG and incident CHD was
ascertained by the ARIC Morbidity and Mortality Classification Committee using data from
follow-up calls, hospitalization records and death certificates.28 Prevalent stroke was defined
as the self-reported physician diagnosis of a stroke prior to visit 1, and following visit 1 was
adjudicated from diagnosis codes indicative of cerebrovascular disease.29 Incident stroke
was defined as the first probable or definite hospitalized stroke occurring in a participant
free of a history of diagnosed stroke at baseline.
Statistical analysis
Inclusion / exclusion criteria—Of the 15,792 participants who attended visit 1 in the
ARIC study, we excluded individuals who were of a racial/ethnic group other than white or
African-American and nonwhites in the Minneapolis and Washington County field centers
(n=103), those with prevalent AF at visit 1 (n=37), low quality or missing ECG (n=309),
those missing lipid levels (n=395), those non-fasting (n=558) and those missing covariates
(n=14). For analysis of lipid levels, those taking cholesterol medications at visit 1 were also
excluded (n=407; 20% statins). The final sample for lipid level analysis included 13,969
participants (25% African-American, 45% male). The association of use of cholesterol-
lowering medications with AF was estimated in 13,044 ARIC participants using visit 2 as
baseline and similar exclusion criteria. Beginning follow-up at visit 2 allowed us to adjust
for lipid levels and covariates from visit 1 as potential confounders.
Lipid level analysis—We categorized individuals by lipid levels according to clinical
categories outlined in the National Cholesterol Education Program Adult Treatment Panel
III guidelines: HDLc categorized as: <40 mg/dL, 40–59 mg/dL, ≥60 mg/dL; LDLc: <100
mg/dL, 100–159 mg/dL, ≥160 mg/dL; total cholesterol: <200 mg/dL, 200–239 mg/dL, ≥240
mg/dL; triglycerides: <150 mg/dL, 150–199 mg/dL, ≥200 mg/dL. 30 For the analysis with
lipid levels as a time-dependent exposure (see below), a measurement of one standard
deviation (SD) increment of each lipid level was used to allow comparisons among different
blood lipid levels. In an additional analysis, we examined the association of changes in
LDLc levels from visit 1 to visit 4 with AF risk, adjusting for covariates from both visits
along with baseline LDLc levels. P-values for trend were calculated including lipid levels as
continuous variables in the models.
We estimated the association of baseline (visit 1) lipid levels with the incidence of AF using
Cox proportional hazards models with time to AF as the main outcome variable. Follow-up
time was defined as the time elapsed between baseline and date of AF incidence, death, lost
to follow-up or December 31, 2007, whichever came earlier. The rate of AF was modeled
using a Cox proportional hazards model with lipid levels as time-varying covariates. Models
were adjusted for baseline covariates including age, sex, race, study site, education (less than
completed high school, high school diploma, at least some college), income (<$16,000,
$16,000–<$35,000, $35,000-<$50,000, ≥$50,000), and height (continuous), and were also
adjusted for the following time-varying covariates: smoking (never, former, current), alcohol
drinking (never, former, current), BMI (continuous), diabetes (dichotomous), systolic blood
pressure (continuous), diastolic blood pressure (continuous), use of antihypertensive
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medications, use of cholesterol lowering medications, prevalent stroke, prevalent HF and
prevalent CHD . An additional model was performed also adjusting for incident stroke,
incident HF and incident CHD as time-varying covariates. The proportional hazards
assumption was tested using time interaction terms and inspection of log negative log
survival curves.
Because most AF events were identified from hospitalizations, we conducted two additional
analyses to evaluate whether associations between lipid levels and AF risk would be biased
because of the method of event ascertainment. First, we determined whether lipid levels
were associated with incidence of any hospitalization, and compared those results with the
association of lipids and AF. Second, we included any hospitalization as a time-dependent
covariate in the models, to determine whether hospitalizations mediated any observed
association between lipid levels and AF.
Lipid-lowering medication analysis—To measure the association between lipid
medication use and the incidence of AF, visit 2 was used as baseline, and models were
adjusted for covariates of interest from visit 1, using similar models as stated above, and in
addition also adjusting for LDLc and triglycerides measured at the previous visit. The
association between lipid medication use and incidence of AF was assessed using Cox
proportional hazards models with time-varying medication use (visits 2, 3 and 4) and
covariates to take into account changes in medication use over time.
In addition to the standard multivariable analyses for lipid medications, we conducted a
secondary analysis using a propensity score approach. 31 We calculated an estimated
propensity score as the probability of receiving treatment at visit 2 given covariates
(previously mentioned) using a logistic model. Secondly, we performed two different
analyses: (1) we conducted a standard Cox model adjusting for the propensity score, and (2)
treated and untreated were matched on their continuous propensity score at a 4:1 ratio with
nearest neighbor matching with no replacement for prior matched control, and analyzed in a
Cox model. Follow-up for this analysis also started in visit 2 in order to adjust for other
covariates measured in the previous visit, including LDLc and triglyceride levels.
We conducted stratified analyses by age and race categories in all lipid levels. Effect
measure modification was formally tested including an interaction term between age and
race variables and levels of each lipid measurement. All statistical analyses were performed
with SAS v 9.2 (SAS Inc, Cary, NC).
Results
Selected characteristics for ARIC participants by categories of total cholesterol are shown in
Table 1. Older participants, women, African-Americans, and those with less education and
income were more likely to have higher levels of total cholesterol. Diabetes, hypertension,
prevalent CHD and prevalent HF were also associated with higher cholesterol.
Blood lipids and AF risk
During a median follow-up of 18.7 years, we identified 1433 incident AF cases. After
adjustment for potential confounders and intermediates, there was no significant association
between baseline levels of HDLc and triglycerides with incident AF (table 2). Higher levels
of LDLc and total cholesterol at baseline were associated with a lower risk of incident AF.
Hazard ratio (HR) and 95% confidence interval (CI) of AF in individuals with LDLc 100–
159 mg/dL was 0.84 (0.72–0.97) and in LDLc ≥160 mg/dL was 0.85 (0.72–1.01) compared
to those with LDLc levels <100 mg/dL (p for trend=0.06). Compared to those with total
cholesterol levels <200 mg/dL, the HR(95% CI) of AF was 0.88 (0.76–1.01) in those with
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levels ≥240 mg/dL (p for trend=0.03). Models not adjusting for prevalent stroke, HF and
CHD, and also models additionally adjusting for incident stroke, HF and CHD produced
similar results. Results of the association between incident AF and each lipid level
measurement at visits 2–4 were similar and are shown in Figure 1. A significant inverse
association was seen between LDLc and total cholesterol and incident AF in most visits,
with stronger associations in later visits. Results were comparable when we considered lipid
levels as time-dependent exposures, also shown in Figure 1. The HR (95% CI) of AF by one
standard deviation increment in time-varying HDLc and triglyceride measurements were
0.97 (0.91–1.04) and 1.00 (0.96–1.04), respectively. HR (95% CI) in time-varying LDLc
measurements was 0.90 (0.85–0.96) and in total cholesterol was 0.89 (0.84–0.95). In
analyses including only AF events identified in study ECGs (n=117), the HR (95% CI) of
AF was 0.79 (0.63–0.98) for LDLc and 0.75 (0.60–0.93) for total cholesterol. Adjustment
for exercise in the models did not change the significance of the association. An additional
analysis was performed examining the change in LDLc from visit 1 to visit 4. After
excluding those on cholesterol medications, and after adjustment for visit 1 and visit 4
covariates and baseline LDLc levels, the HR (95% CI) for 1 mmol/L change of LDLc was
0.79 (0.69–0.90). These results indicate that the larger the decrease in LDLc from visit 1 to
visit 4, the lower the risk of AF. LDLc was not associated with overall risk of
hospitalizations (HR 0.98, 95% CI 0.96–1.00, for 1-SD increment), and adjustment for
hospitalizations as a time-dependent covariate did not change the association between LDLc
and AF risk (HR 0.91, 95% CI 0.86–0.97 for 1-SD LDLc increment as a time-dependent
covariate).
AF-free survival curves from visit 1 and visit 4 by LDLc cholesterol levels are shown in
figure 2, with higher survival in those with higher LDLc. There was no significant age or
race interaction between HDLc, LDLc and total cholesterol levels. However, the association
of triglyceride levels with AF risk varied by race (p=0.02), with a stronger association in
African-Americans compared to whites (HR (95%CI) = 1.14 (1.03–1.26) and 0.99 (0.94–
1.03), respectively).
Lipid-lowering medication use and AF risk
We assessed the association of use of cholesterol medications with AF risk, considering visit
2 as baseline while adjusting for covariates from the previous visit. Among the 13,044
eligible participants, 2102 were on some cholesterol-lowering medication at one or more
visits, with 68% of those taking statins at some point (39% at visit 2, 59% at visit 3, 80% at
visit 4). There were 1311 incident AF cases identified, and of those occurring in cholesterol
medication users (278 events), 68% occurred in those taking statins. After multivariable
adjustment, there was no association between time-varying cholesterol medication use
across visits and the incidence of AF with a HR (95% CI) of 0.96 (0.82–1.13) compared to
those not on cholesterol-lowering medications (table 3). There was also no association
between those taking statins compared to those taking other cholesterol medications, HR
(95% CI) = 0.91 (0.66–1.25). Models not adjusting for prevalent stroke, heart disease and
CHD, and also models additionally adjusting for incident stroke, heart disease and CHD
produced similar results.
A secondary analysis was performed using propensity scores calculated at visit 2. In a
standard Cox model, the propensity score-adjusted HR (95% CI) was 1.09 (0.88–1.34)
comparing lipid-lowering medication use versus non-users, and when matched 4:1 (not-
treated: treated) by propensity score, results were similar HR (95% CI) = 1.03 (0.89–1.20).
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In this population-based prospective study, we found no independent association between
HDLc or triglycerides and incidence of AF, while lower levels of LDLc and total cholesterol
were associated with a higher AF risk. We also found no independent association between
lipid-lowering medications, including statins, and the risk of AF. These associations were
independent of lifestyle factors, clinical factors and cardiovascular disease, and were similar
with regards to whites and African Americans.
Blood lipid levels and AF
The relationship between lipid levels and AF risk has not been extensively addressed.
Previous publications reported low HDLc levels were associated with a 20–40 % higher risk
of AF; 7–9 however, residual confounding could have been responsible for that association.
In our analysis, an initial association between HDLc and AF risk disappeared after
adjustment for a wide selection of potential confounders. Similar results were observed for
triglycerides.
The inverse association of LDLc and total cholesterol with AF risk is intriguing, and has
been previously seen in an analysis of the Cardiovascular Health Study, which included
individuals aged 65 and older.11 Similar results were found in two Japanese populations, in
which individuals with hypercholesterolemia had a 25% lower odds of developing AF, and
an 8% reduction in AF risk with each 10% increase in LDLc.9, 32 Notably, this association
was stronger in older individuals, consistent with our results of stronger inverse associations
in later ARIC visits. No clear mechanism exists to explain this association, however. Sub-
clinical hyperthyroidism might be potentially responsible, since hyperthyroidism reduces
levels of total and LDLc cholesterol,33 and is associated with increased risk of AF.34
Unfortunately, we do not have information on thyroid profiles in ARIC participants. Blood
lipids could also impact the composition of cell membranes, which is a major determinant of
cell excitability. In vitro studies have shown that cholesterol modulates the distribution and
function of some ion channels potentially involved in the occurrence of AF, such as the
Kv1.5 potassium channel.35, 36 Whether this mechanism explains the observed association is
hypothetical and requires further research.
Lipid lowering medications and AF
Published reports addressing the relationship between statins and AF have provided
inconsistent results and the conclusions tend to be different based on clinical trials (no
association) or observational studies (reduced AF risk).21 This study provided results
consistent with those seen in most randomized clinical trials, and indicated no relationship
between statin use or any lipid-lowering medication use and the risk of AF. During the years
the ARIC visits were conducted (1987–1998) statins were gaining in popularity, and that,
combined with the participants getting older, meant the majority of statin users were not
taking them until around visit 4 (1996–98). There have been no study visits since 1998, so
we were unable to determine how many of the participants with incident AF were receiving
statins or lipid-lowering medications in the years between visit 4 and the year in which their
AF occurred.
Strengths and limitations
Some other study limitations should be noted. Asymptomatic AF and AF managed
exclusively in an outpatient setting could not be identified, as most of our incident AF cases
were ascertained from hospitalization discharge records. However, it has been shown the
incidence rates of AF in the ARIC study are consistent with other population-based studies,
and the validity of AF ascertainments using hospitalizations is acceptable.3 In a sub-analysis
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in this study comparing AF ascertained from hospital records versus ECGs, there was an
even stronger inverse association seen between LDLc (HR=0.79 for ECGs; HR=0.90 for
hospital records) and total cholesterol (HR=0.75 for ECGs; HR=0.89 for hospital records)
and incident AF in the ECG group, thus supporting evidence that AF ascertained from
hospitalizations is acceptable. Also, LDLc levels were not associated with the risk of
hospitalization, and adjustment for incident hospitalizations before AF incidence or
censoring did not change the association between LDLc and AF. There is also the possibility
those with dyslipidemia have more paroxysmal AF that was not captured by our AF
ascertainment process. Other limitations include the possible misclassification of exposures,
both lipid levels and lipid-lowering medications, due to unmeasured changes between visits.
Along with no data on thyroid hormones, which might confound our results, the ARIC study
also does not contain information on the dose of statins or other lipid medications. Higher
doses have a stronger effect on cholesterol levels and other processes (such as inflammation
in the case of statins), and therefore different doses may affect differentially the incidence of
AF. Also, we cannot determine the impact of lifestyle changes a patient may incorporate to
become healthier after discovering they have high cholesterol. Despite these limitations, our
study has important strengths including a large sample size, a long follow-up, an elevated
number of AF events, a biracial sample, and an extensive list of measured covariates.
Conclusion
In conclusion, we found that higher levels of LDLc and total cholesterol were associated
with a lower incidence of AF independently of other risk factors. HDLc and triglycerides,
however, were not independently associated with AF incidence after multivariable
adjustment. Future research should replicate these results and study potential mechanisms.
Additionally, no association was found between lipid-lowering medication, including
statins, and the incidence of AF. At this time, there is still insufficient data to recommend
the use of statins solely for AF prevention.
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Hazard Ratio and 95% confidence intervals of atrial fibrillation according to lipid level
measurements at each visit, and as a time-varying variable, ARIC, 1987–2007. Results from
separate Cox proportional hazard models adjusted for age, sex, race, study site, education,
income, height, smoking status, drinking status, body mass index, systolic blood pressure,
diastolic blood pressure, use of antihypertensive medication, diabetes, prevalent stroke,
prevalent heart failure, prevalent coronary heart disease, and use of cholesterol medications
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Kaplan Meier survival curves for atrial fibrillation (AF) by categories of LDLc cholesterol
(<100, 100–159, ≥160 mg/dL) from baseline (top panel) and from visit 4 (bottom panel),
ARIC 1987–2007 and 1996–2007, respectively. Cox proportional hazards model excluding
those on cholesterol-lowering medications at baseline, and adjusted for age, sex, study site,
education, income, height, smoking status, drinking status, body mass index, systolic blood
pressure, diastolic blood pressure, use of antihypertensive medication, diabetes, prevalent
stroke, prevalent heart failure, and prevalent coronary heart disease. P for trend is considered
across categories. The number of subjects at risk throughout the duration of the study
follow-up are shown on the x-axis.
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Table 1








Number of participants 5458 5246 3265
Age, years 53.2 (5.8) 54.4 (5.7) 55.3 (5.6)
Men, % 48.1 44.3 39.1
African-American, % 26.5 22.3 27.9
High school degree, % 78.7 77.4 74.5
Income ≥$50,000, % 26.7 24.0 19.4
Current smoker, % 26.7 24.4 26.6
Current alcohol use, % 57.6 56.9 55.1
BMI, kg/m2 27.4 (5.5) 27.6 (5.4) 27.9 (5.0)
Height, cm 169.4 (9.3) 168.4 (9.3) 167.0 (9.2)
Diabetes, % 8.6 9.8 12.2
Systolic blood pressure, mmHg 119.2 (18.4) 121.3 (18.6) 123.3 (19.2)
Diastolic blood pressure, mmHg 73.0 (11.3) 73.7 (11.1) 74.6 (11.2)
Anti-hypertensive medications, % 26.3 29.0 32.9
Prevalent coronary heart disease, % 3.4 4.5 5.1
Prevalent stroke, % 1.6 1.9 1.6
Prevalent heart failure, % 3.9 4.3 4.2
Values correspond to mean (SD) or percentage. BMI: body mass index
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Table 3





Number of participants 10942 2102
AF cases 1033 278




Number of participants 666 1436
AF cases 89 189
Hazard ratio (95% CI)* 1 (REF) 0.91 (0.66–1.25)
*
Cox proportional hazard model with time-varying medication use and adjusted for age, sex, race, study site, education, income, and time-varying
(from the previous visit) height, smoking status, drinking status, body mass index, systolic blood pressure, diastolic blood pressure, use of
antihypertensive medication, diabetes, prevalent stroke, prevalent heart failure, prevalent coronary heart disease, LDLc cholesterol and triglyceride
levels
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